Dr Ayodeji A Asuni is a neurobiologist with a degree in Biochemistry and a PhD in Neuroscience from Kings’ College London. Institute of Psychiatry, Psychology and Neuroscience. His PhD training was followed by post-doctoral fellowship training at New York University (working with Prof. Einar Sigurdsson) and University of Southampton (Working with Prof. Vincent O’Connor and Prof. Hugh Perry). This was followed by a Research Assistant Prof position at NYU, and a Teaching position at University of Southampton.
Dr Asuni has over 15 years of biomedical research experience (academia and pharmaceutical industry) and a proven track record of delivery in both sectors. With broad translational biology expertise in therapeutic areas including Alzheimer’s disease, Migraine, as well as in Neuroinflammation and Neuroimmunology.
His current focus is on drug discovery at the interphase of preclinical and clinical research, developing treatment approaches for migraine, as well as preclinical research on neuroimmune mechanisms in CNS disorders and work on exploratory fluid biomarker correlates in preclinical mechanistic models.
As an academic researcher, Dr Asuni has contributed to amyloid-targeted and tau-targeted immunotherapy studies in transgenic mice and non-human primates. He was the first demonstration the potential efficacy of tau targeted immunotherapy for Alzheimer’s disease. This idea has now been translated to the clinic by several pharma companies.
Dr Asuni has mentored several Master and PhD students, is an author on granted patents, 58 publications with over 2800 citations. A list of his publications can be found on Google Scholar.
He currently heads the department of Preclinical Fluid Biomarker and Occupancy at Lundbeck.